Chronic Lymphocytic Leukemia

CLINICAL_TRIALS trial_result · 2025-08-03

Clinical Trial Update: Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies [Phase 1]

Phase 1 clinical trial update on genetically engineered CAR T cells (EGFRt/19-28z/IL-12) for relapsed or refractory CD19+ hematologic malign…

CLINICAL_TRIALS trial_result · 2025-07-24

Clinical Trial Update: Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy [Phase 2]

Phase 2 trial evaluating ibrutinib for achieving minimal residual disease negativity in patients with chronic lymphocytic leukemia after fro…

CLINICAL_TRIALS trial_result · 2025-07-08

Clinical Trial Update: CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 [Phase 2]

A Phase 2 clinical trial (CTRIAL-IE 07-01) for chronic lymphocytic leukemia conducted by Cancer Trials Ireland has completed. The document n…

CLINICAL_TRIALS trial_result · 2025-07-03

Clinical Trial Update: Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies [Phase 1]

Phase 1 clinical trial evaluating human anti-CD19 CAR-T cells for relapsed or refractory lymphoid malignancies is currently active but not r…

CLINICAL_TRIALS trial_result · 2025-07-01

Clinical Trial Update: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) [Phase 1]

Phase 1 study update for CD19 CAR-allogeneic NKT therapy (ANCHOR) in relapsed or refractory B-cell malignancies; the trial is currently acti…

CLINICAL_TRIALS trial_result · 2025-07-01

Clinical Trial Update: Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study [Phase 2]

Phase 2 DIRECT trial evaluating daratumumab with ibrutinib for relapsed or refractory chronic lymphocytic leukemia was terminated, with resu…

CLINICAL_TRIALS trial_result · 2025-06-29

Clinical Trial Update: A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom

A completed UK trial evaluating changes in patient experience for adults with chronic lymphocytic leukemia treated with venetoclax plus ritu…

CLINICAL_TRIALS trial_result · 2025-06-22

Clinical Trial Update: A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) [Phase 1]

This update covers the completed Phase 1 study of the investigational drug JNJ-67856633 in participants with non-Hodgkin lymphoma and chroni…

CLINICAL_TRIALS trial_result · 2025-06-10

Clinical Trial Update: Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG) [Phase 2]

Phase 2 trial evaluating a sequential regimen of bendamustine debulking followed by venetoclax (ABT-199) and obinutuzumab (GA101) induction …

CLINICAL_TRIALS trial_result · 2025-06-10

Clinical Trial Update: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma [Phase 1]

Phase 1 trial of selinexor in combination with ibrutinib for relapsed or refractory chronic lymphocytic leukemia and aggressive non-Hodgkin …

CLINICAL_TRIALS trial_result · 2025-06-08

Clinical Trial Update: Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL [Phase 2]

Phase 2 study evaluating the efficacy of acalabrutinib in very old or frail patients with treatment-naïve or relapsed/refractory chronic lym…

CLINICAL_TRIALS trial_result · 2025-06-04

Clinical Trial Update: Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation [Phase 2]

Phase 2 trial comparing three GVHD prophylaxis regimens in nonmyeloablative or reduced-intensity conditioning unrelated donor transplantatio…

CLINICAL_TRIALS trial_result · 2025-06-03

Clinical Trial Update: RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

A two-stage Phase 1/2 trial evaluating RP-3500 in combination with Olaparib for DNA damage repair pathway-deficient relapsed/refractory chro…

CLINICAL_TRIALS trial_result · 2025-06-03

Clinical Trial Update: A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL [Phase 1]

Phase I study of ONO-4685 as monotherapy to evaluate tolerability and safety in relapsed or refractory T cell lymphoma and chronic lymphocyt…

CLINICAL_TRIALS trial_result · 2025-05-25

Clinical Trial Update: Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza [Phase 1]

Phase 1 blinded cross-over bioequivalence trial comparing Luitpold azacitidine with Vidaza has completed, with results posted.

CLINICAL_TRIALS trial_result · 2025-05-21

Clinical Trial Update: MEOI and HRQoL in CLL Patients Treated With BTKis

A clinical trial evaluating MEOI and health-related quality of life in chronic lymphocytic leukemia patients treated with BTK inhibitors has…

CLINICAL_TRIALS trial_result · 2025-05-13

Clinical Trial Update: VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib [Phase 1]

This Phase 1 trial evaluated VAY736 in combination with ibrutinib in patients with chronic lymphocytic leukemia who were on ibrutinib. The s…

CLINICAL_TRIALS trial_result · 2025-04-29

Clinical Trial Update: Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma [Phase 1]

Phase 1 clinical trial evaluating pentostatin, bendamustine, and ofatumumab for chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma…

CLINICAL_TRIALS trial_result · 2025-04-24

Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]

Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …

CLINICAL_TRIALS trial_result · 2025-04-17

Clinical Trial Update: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation [Phase 3]

Phase 3 trial comparing venetoclax plus obinutuzumab against FCR/BR in previously untreated chronic lymphocytic leukemia has completed and p…

CLINICAL_TRIALS trial_result · 2025-04-16

Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]

Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgki…

CLINICAL_TRIALS trial_result · 2025-04-16

Clinical Trial Update: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL [Phase 1, Phase 2]

A clinical trial is evaluating APG2575 as both a single agent and in combination therapy for relapsed/refractory chronic lymphocytic leukemi…

CLINICAL_TRIALS trial_result · 2025-04-10

Clinical Trial Update: A Study Of The Selective PKC-β Inhibitor MS- 553 [Phase 1, Phase 2]

A Phase 1/2 study of the selective PKC-β inhibitor MS-553 in chronic lymphocytic leukemia, small lymphocytic lymphoma, and aggressive lympho…

CLINICAL_TRIALS trial_result · 2025-04-06

Clinical Trial Update: Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors [Phase 2]

A Phase 2 trial evaluating α/β+-T lymphocyte-depleted donor grafts from HLA-mismatched donors in multiple hematologic malignancies was termi…

CLINICAL_TRIALS trial_result · 2025-03-28

Clinical Trial Update: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers [Phase 1]

Aplitabart (IGM-8444) Phase 1a/1b study in solid tumors and various hematologic cancers was terminated.

Top drugs studied for this disease